CSF2 and melanoma: OPTiM (Oncovex Pivotal Trial in Melanoma) was a Phase III randomized clinical trial that evaluated the efficacy and safety of T-VEC compared to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with unresectable stage IIIB-IV melanoma.